Top 5 Drug Type | Count |
---|---|
Small molecule drug | 10 |
Proteolysis-targeting chimeras (PROTAC) | 9 |
Diagnostic radiopharmaceuticals | 8 |
Chemical drugs | 3 |
Peptide Conjugate Radionuclide | 2 |
Target |
Mechanism PPARδ agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date14 Aug 2024 |
Target |
Mechanism VEGF-A inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PDL1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseClinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Mar 2025 |
Sponsor / Collaborator |
Start Date01 Sep 2024 |
Sponsor / Collaborator |
Start Date12 Jul 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Bevacizumab-IRDye800CW(University of Groningen) ( VEGF-A ) | Rectal Cancer More | Phase 1 |
89Zr-CX-072 ( PDL1 ) | Neoplasms More | Clinical |
Seladelpar ( PPARδ ) | Primary Biliary Cholangitis More | Preclinical |
BsAb CD73xEGFR(University of Groningen) ( CD73 x EGFR ) | Solid tumor More | Preclinical |
HD-TAC2 ( HDAC3 ) | Inflammation More | Preclinical |